Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Active Biotech AB - Interim report January - June 2017

Active Biotech
Posted on: 10 Aug 17

   
Second quarter in brief

  • In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
  • The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate and MRI-data) were achieved and in line with previous studies
  • Out-licensing activities are continuing for tasquinimod, paquinimod and SILC

Events after the end of the period

  • Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company July 1, 2017
  • In July, a patent application for the use of ANYARA in combination with PD-1 inhibitors for the treatment of cancer was published on WIPO's (World Intellectual Property Organization) website www.wipo.int
     

Financial summary

SEK M April-June Jan.-June Full-year
  20172016201720162016
      
Net sales5.13.99.87.919.0
Operating loss-23.1-14.5-37.7-30.6-55.1
Loss for the period-24.4-15.5-40.2-32.3-59.6
Loss per share, before and after dilution (SEK)-0.25-0.17-0.42-0.36-0.65
Cash and cash equivalents (at the end of the period)  47.757.477.7

For further information, please contact:

  Helén Tuvesson, President & CEO
  Tel: +46 (0)46-19 21 56

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: 046 (0)46-19 20 00

 

The report is also available at www.activebiotech.com .

Active Biotech AB - Interim report January – June 2017


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire
HUG#2126480
GlobeNewswire
globenewswire.com

Last updated on: 11/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.